Mild Alzheimer's, Mild Cognitive Impairment
A Study of Lanabecestat (LY3314814) in Participants With Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug LY3314814 in participants with early Alzheimer's disease dementia at the time of entry into study I8D-MC-AZES.
This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.
Your participation could last up to 56 weeks and include at least 13 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participants must have been previously enrolled in AMARANTH (NCT02245737) study